UK markets closed
  • NIKKEI 225

    28,820.09
    -278.15 (-0.96%)
     
  • HANG SENG

    25,555.73
    -73.01 (-0.28%)
     
  • CRUDE OIL

    83.11
    +0.45 (+0.54%)
     
  • GOLD FUTURES

    1,800.80
    +2.00 (+0.11%)
     
  • DOW

    35,730.48
    +239.79 (+0.68%)
     
  • BTC-GBP

    44,600.39
    +1,651.36 (+3.84%)
     
  • CMC Crypto 200

    1,491.73
    +72.36 (+5.10%)
     
  • ^IXIC

    15,448.12
    +212.28 (+1.39%)
     
  • ^FTAS

    4,137.54
    -1.14 (-0.03%)
     

Spain's Grifols to buy rival Biotest for up to $1.9 billion

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
Grifols's medicine is displayed in their headquarters in Sant Cugat del Valles, near Barcelona
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry.

Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. It has also offered to buy the remaining shares trading on the Frankfurt stock market.

The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.

Grifols will then offer Biotest's minority shareholders 43 euros per ordinary share, a roughly 22% premium on Thursday's closing price, and 37 euros per preferred share.

If all shareholders tender their shares, Grifols would pay a total of 1.6 billion euros for Biotest.

Ordinary shares of Biotest were trading close to the price offered by Grifols, while the shares of Grifols were down 1.6% at 20.31 euros in late morning trading.

The deal "will enlarge our existing portfolio of plasma-derived therapies and fast-track the development of new products," Grifols' co-CEO Raimon Grifols Roura said in a statement.

The merger would lift the family firm's earnings before interest, taxes, depreciation and amortisation by 300 million euros in 2024 and 600 million euros in 2026, co-CEO Victor Grifols said in a call with analysts.

"Overall, we think the deal makes strategic sense and continuing to scale up internationally and consolidate the existing plasma oligopoly should help reassure on Grifols' ability to outgrow impending competitive pressures," Deutsche Bank said in a note to investors on Friday.

The deal will also boost Grifols' capacity to collect plasma, a bottleneck for its development, thanks to Biotest's 26 European plasma centres.

The company expects to conclude the merger by the end of the first half of 2022 after clearing all regulatory hurdles.

($1 = 0.8495 euros)

(Reporting by Inti LandauroEditing by Mark Potter and David Evans)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting